Alex Arfaei Recent News
Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval
Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals
Last Night's Election - A Series Of Fortunate Events For Big Pharma
BMO Capital Upgrades Merck To Outperform, Bullish On Co
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
BMO Shows Concern With AbbVie's Major Growth Drivers, Downgrades To Market Perform
BMO Valeant Reaction: 10-K Could Give Investors Confidence To Value Shares Above $60
BMO Still Believes Valeant Is Undervalued
Some On Wall Street Still Back Valeant
BMO Downgrades Whole Foods And Bristol-Myers Squibb To Start Week: Why?
BMO Thinks Valeant's Structure Is 'Questionable,' Says Investigation May Be Needed To Resolve Uncertainty
Calls Of Note: Wall Street Research Moving The Market On Thursday
BMO Downgrades Zoetis After Valeant Report
BMO's Updated Eli Lilly Model Following Earnings
UPDATE: BMO Capital Downgrades Pfizer
UPDATE: BMO Downgrades Bristol-Myers Squibb
UPDATE: BMO Capital Upgrades Eli Lilly
UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook
Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment
UPDATE: BMO Capital Markets Lowers PT on Merck Following New SGLT2 Data